Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to examine the efficacy and safety of 24 weeks treatment with theophylline plus low-dose formoterol-budesonide in subjects with bronchiectasis.
Non-cystic fibrosis bronchiectasis is an orphan disease caused by the pathogenic vicious circle including infection, inflammation and airway repair. Today's principle of treatment is to break the cycle of inflammation and infection. Nowadays, most clinical trials are anti-infective treatment by antibiotics trying to break this cycle by reducing the bacterial load, which may cause bacterial resistance. There were still some anti-inflammation trials by using inhaled corticosteroids(ICS). Tsang and Martínez-García showed that inhaled corticosteroids reduced IL-1,IL-8 levels and sputum inflammation cells, and improved sputum volume as well as quality of life, though the corticosteroid must be high dose or medium dose combined with long-acting ß2 adrenergic agonists. As described in asthma and chronic obstructive pulmonary disease(COPD), theophylline can improve the activity of histone deacetylase (HDAC) and then enhanced the anti-inflammatory effect of steroids. We hypothesis that theophylline may have the same effect in subjects with bronchiectasis. Theophylline plus inhaled low-dose formoterol-budesonide may improve quality of life and reduce airway inflammation.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo+formoterol-budesonide | Placebo Comparator | Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks. Inhaled Formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks. |
|
| Theophylline+formoterol-budesonide | Experimental | Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks. Inhaled formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Formoterol-budesonide | Drug | Formoterol-budesonide combined treatment (4.5µg/160µg Q12H) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Life Assessment with St George's Respiratory Questionnaire(SGRQ) and Leicester Cough Questionnaire(LCQ) | Baseline and 24 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Mean number of exacerbations per patient per 24 weeks | Exacerbations defined by persistent (≥ 24 h) deterioration in at least three respiratory symptoms, including cough, dyspnea, hemoptysis, increased sputum purulence or volume, chest pain (with or without fever). | Baseline and 24 weeks |
| Changes of sputum characteristics from baseline to 24 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chen Rongchang, Professor | institute vice director | Study Director |
| Zhong Nanshan, Professor | institute director | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| State Key Laboratory of Respiratory Research Institute. | Guangzhou | Guangdong | 510000 | China | ||
| The First Affiliated Hospital of Guangzhou Medical University |
Not provided
| ID | Term |
|---|---|
| D001987 | Bronchiectasis |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D013806 | Theophylline |
| ID | Term |
|---|---|
| D014970 | Xanthines |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D011688 | Purinones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Theophylline | Drug | Theophylline 0.1 Q12H |
|
|
| Placebo | Drug | Placebo for theophylline 0.1 Q12H |
|
| Baseline and 24 weeks |
| Changes of 24 hour sputum volume from baseline to 24 weeks | Baseline and 24 weeks |
| Changes of forced expiratory volume in 1 second(FEV1) from baseline to 24 weeks | Baseline and 24 weeks |
| Changes of mean forced expiratory flow between 25% and 75% of the FVC(FEF25-75)from baseline to 24 weeks | Baseline and 24 weeks |
| Changes of forced vital capacity(FVC) from baseline to 24 weeks | Baseline and 24 weeks |
| Changes of peak expiratory flow(PEF) from baseline to 24 weeks | Baseline and 24 weeks |
| Induced sputum cytology count | Baseline and 24 weeks |
| Changes of sputum culture from baseline to 24 weeks | Baseline and 24 weeks |
| IL-6 | Test IL-6 both in blood and sputum. | Baseline and 24 weeks |
| IL-8 | Test IL-8 both in blood and sputum. | Baseline and 24 weeks |
| IL-10 | Test IL-10 both in blood and sputum. | At 24 weeks |
| Tumor necrosis factor(TNF)α | Test TNF-α both in blood and sputum. | Baseline and 24 weeks |
| Activity of histone deacetylase(HDAC) | HDACs are extracted from cells in blood. | Baseline and 24 weeks |
| Activity of histone acetyltransferase(HAT) | HATs are extracted from cells in blood. | Baseline and 24 weeks |
| 8-Isoprostane | Baseline and 24 weeks |
| Neutrophilic granulocytes in blood routine examination | Baseline and 24 weeks |
| White blood cells in blood routine examination | Baseline and 24 weeks |
| Monocytes in blood routine examination | Baseline and 24 weeks |
| Eosinophilic granulocytes in blood routine examination | Baseline and 24 weeks |
| Number of participants with Adverse events as a measure of safety and tolerability | Adverse events may contain symptoms such as nausea, sickness, headache, insomnia, palpitation, arrhythmia and so on. Record the symptoms and times of the patients. | 24 weeks |
| Plasma Concentration of Theophylline | Venous blood was taken for plasma theophylline at the end of the treatment period. (At the very time of 2 hours after patients taken the pills) | 24 weeks |
| Guangzhou |
| Guangdong |
| 510000 |
| China |
| D011687 |
| Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |